Actively Recruiting
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
Led by Eli Lilly and Company · Updated on 2026-01-14
495
Participants Needed
23
Research Sites
149 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to find out whether the study drug, LY4170156, is safe, tolerable and effective in participants with advanced solid tumors. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.
CONDITIONS
Official Title
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Have one of the following solid tumor cancers: ovarian (epithelial ovarian, primary peritoneal, and fallopian tube), endometrial, cervical, non-small cell lung, triple negative breast, pancreatic, or colorectal cancer
- For dose optimization: ovarian (epithelial ovarian, primary peritoneal, and fallopian tube) and endometrial cancer
- For dose expansion: low grade serous ovarian cancer, cervical cancer, non-small cell lung cancer, or triple negative breast cancer
- Be aged 18 years or older
You will not qualify if you...
- Known or suspected uncontrolled central nervous system metastases
- History of carcinomatous meningitis
- Active uncontrolled systemic bacterial, viral, fungal, or parasitic infection
- Evidence of corneal keratopathy or history of corneal transplant
- Any serious unresolved toxicities from prior therapy
- Significant cardiovascular disease
- Prolongation of QT interval corrected for heart rate using Fridericia's formula (QTcF) 64 470 milliseconds
- History of pneumonitis or interstitial lung disease
- Pregnant, breastfeeding, or planning to breastfeed during study or within 30 days after last dose of study intervention
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 23 locations
1
HonorHealth
Scottsdale, Arizona, United States, 85258
Actively Recruiting
2
University of California, San Diego (UCSD) - Moores Cancer Center
La Jolla, California, United States, 92037
Actively Recruiting
3
South Texas Accelerated Research Therapeutics (START) Midwest
Grand Rapids, Michigan, United States, 49546
Actively Recruiting
4
NYU Langone Health - Long Island
Mineola, New York, United States, 11501
Actively Recruiting
5
New York University (NYU) Clinical Cancer Center
New York, New York, United States, 10016
Actively Recruiting
6
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
Actively Recruiting
7
The Ohio State University (OSU) Wexner Medical Center
Columbus, Ohio, United States, 43210
Actively Recruiting
8
The University of Texas - MD Anderson Cancer Center
Houston, Texas, United States, 77030-4000
Actively Recruiting
9
START Mountain Region
West Valley City, Utah, United States, 84119
Actively Recruiting
10
Cancer Research SA
Adelaide, Australia, 5000
Actively Recruiting
11
Icon Cancer Centre South Brisbane
QLD, Australia, 4101
Actively Recruiting
12
Centre Leon Berard
Lyon, France, 69373
Actively Recruiting
13
Institut de Cancerologie de l'Ouest - site St-Herblain
Saint-Herblain, France, 44805
Actively Recruiting
14
Oncopole Claudius Regaud
Toulouse, France, 31059
Actively Recruiting
15
Istituto Europeo di Oncologia
Milan, Italy, 20141
Actively Recruiting
16
Istituto Clinico Humanitas
Rozzano, Italy, 20089
Actively Recruiting
17
Shizuoka Cancer Center
Shizuoka, Japan, 411-8777
Actively Recruiting
18
National Cancer Center Hospital
Tokyo, Japan, 104-0045
Actively Recruiting
19
Cancer Institute Hospital of JFCR
Tokyo, Japan, 135-8550
Actively Recruiting
20
National Cancer Center
Goyang-si Gyeonggi-do, South Korea, 10408
Actively Recruiting
21
Hospital Universitario Vall d'Hebron
Barcelona, Spain, 08035
Actively Recruiting
22
Hospital Universitario 12 de Octubre
Madrid, Spain, 28041
Actively Recruiting
23
Hospital Clinico Universitario de Valencia
Valencia, Spain, 46010
Actively Recruiting
Research Team
T
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
CONTACT
P
Physicians interested in becoming principal investigators please contact
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
9
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here